Loading organizations...
§ Private Profile · East Road, Cambridge, Cambridgeshire, CB1 1BH, United Kingdom
MedTech company developing CUE1, a non-invasive wearable device using vibratory stimulation to alleviate Parkinson's movement symptoms.
Based in London, United Kingdom, Charco Neurotech develops and manufactures a non-invasive wearable medical device called CUE1 that utilizes targeted vibratory stimulation to alleviate movement symptoms associated with Parkinson’s disease. The medical technology enterprise commercializes this proprietary hardware directly to consumers, currently supporting approximately 1,600 active patients managing their long-term neurological conditions. Prior to its initial commercial rollout, the organization accumulated a substantial consumer backlog, registering a waiting list of over 6,000 individuals seeking early access to the therapeutic wearable. To finance its manufacturing pipeline and operational expansion across the European market, the firm secured $10 million in a 2021 seed funding round backed by institutional investors including Amadeus Capital Partners, Parkwalk Advisors, Mint Venture Partners, and the Imperial College Innovation Fund. Charco Neurotech was officially established in 2019 by principal founder Lucy Jung.
Charco Neurotech has raised $10.0M across 1 funding round.
Charco Neurotech has raised $10.0M in total across 1 funding round.
Charco Neurotech has raised $10.0M across 1 funding round. Most recently, it raised $10.0M Seed in November 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 1, 2021 | $10M Seed | Parkwalk Advisors, Pierre Socha | Amadeus Capital Partners, Crista Galli Ventures, Mint Venture Partners, University OF Tokyo Edge Capital | Announced |
Charco Neurotech is a Cambridge-based medtech company founded in 2019 that develops a non-invasive wearable medical device called the CUE1, designed to improve movement and quality of life for people with Parkinson’s disease. The device uses pulsed cueing and high-frequency focused vibrotactile stimulation to alleviate symptoms such as slowness, stiffness, rigidity, and freezing of gait. Charco primarily serves individuals with Parkinson’s and healthcare providers, aiming to offer a simple, effective therapeutic option that can be prescribed through health systems like the NHS and Medicaid. The company has demonstrated strong growth, raising over $10 million in funding, employing around 38 people across the UK, South Korea, and the US, and having sold over 3,000 devices with ongoing regulatory approvals underway[1][3][4].
Charco Neurotech was co-founded by Lucy Jung, who brought personal insight into patient needs after her own health challenges and research on Parkinson’s therapies. The idea emerged from university research and evolved through close collaboration with the Parkinson’s community and clinical experts. Early traction included pilot studies showing clinically significant improvements in movement and partnerships with institutions like Addenbrookes Hospital to integrate the device into patient care. The company’s participation in accelerator programs such as Medtech SuperConnector and Cambridge Judge Business School helped shape its strategic direction and growth[1][2][4][5].
Charco Neurotech rides the growing trend of digital and wearable health technologies aimed at managing chronic neurological conditions. The timing is favorable due to increasing Parkinson’s prevalence globally, rising demand for non-pharmaceutical therapies, and advances in wearable sensor and stimulation technologies. The company’s approach exemplifies a shift toward patient-centered, data-driven, and non-invasive interventions that can be integrated into healthcare systems. By improving symptom management and potentially reducing hospital stays, Charco contributes to evolving standards of care and supports the broader ecosystem of neurotechnology innovation[1][2][4].
Looking ahead, Charco Neurotech is positioned to expand its market reach with regulatory approvals in the US and Europe, scale production, and enhance its digital ecosystem through the CUE app for symptom tracking and medication reminders. Trends such as personalized medicine, remote patient monitoring, and integration of AI in neurotherapeutics will likely shape its trajectory. As the company grows, it may influence broader adoption of wearable neurostimulation devices and inspire further innovation in managing Parkinson’s and other neurological disorders. Charco’s commitment to community collaboration and scientific rigor suggests it will remain a key player in improving quality of life for people with Parkinson’s[1][3][4].
Charco Neurotech has raised $10.0M in total across 1 funding round.
Charco Neurotech's investors include Parkwalk Advisors, Pierre Socha, Amadeus Capital Partners, Crista Galli Ventures, Mint Venture Partners, University of Tokyo Edge Capital.